Treatment of malignant melanoma with methyl CCNU.
D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001830:Body Surface Area; D002986:Clinical Trials as Topic; D003510:Cyclohexanes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006410:Hematopoiesis / Q000187:drug effects; D006801:Humans; D007668:Kidney / Q000187:drug effects; D007958:Leukocyte Count; D008099:Liver / Q000187:drug effects; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D009607:Nitrosourea Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000139:chemically induced; D013997:Time Factors
D000970:Antineoplastic Agents; D003510:Cyclohexanes; D009607:Nitrosourea Compounds